MiMedx still a top pick, says Canaccord Canaccord reiterated its Buy rating and top pick designation for MiMedx following the company's raised guidance. The firm believes fundamentals are in place to drive execution in wound care for the foreseeable future as the company's increase in sales force remains ahead of plan and reimbursement changes support growth and increased expectations. Canaccord has a $12 price target on the stock.
News For MDXG From The Last 14 Days
Check below for free stories on MDXG the last two weeks.